AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT05367440
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833
Phase 1
Completed
- Conditions
- ER-positive, HER2-negative Breast Cancer
- Interventions
- Drug: [14C]AZD9833 Oral Solution, 75 mg
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05364255
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Completed
- Conditions
- Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT05364931
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD2373 subcutaneous injectionDrug: Placebo
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT05351047
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 3
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1035
- Registration Number
- NCT05348577
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
Phase 4
Completed
- Conditions
- HyperkalaemiaChronic Kidney Disease
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (SZC)Drug: Local standard of care
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 186
- Registration Number
- NCT05347693
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
Himalaya Early Access Program
- Conditions
- Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT05345678
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab
Phase 1
Completed
- Conditions
- Healthy Participants Study
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT05339100
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 287
- Registration Number
- NCT05329194
- Locations
- 🇺🇸
Research Site, Vancouver, Washington, United States
Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries
Completed
- Conditions
- COVID-19
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT05315323
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
© Copyright 2025. All Rights Reserved by MedPath